AYTU
NEUTRAL
$2.7
Live
Aytu BioPharma, Inc. · NASDAQ
Target $9.33
(+245.7%)
$0.95
52W Range
$3.07
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$27.51M
P/E
N/A
ROE
-50.2%
Profit margin
-20.5%
Debt/Equity
1.23
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.
Key Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Forward P/E of 15.88 is below sector average (220.68), suggesting relative value
Recent price momentum is positive (+61.7% over 1 year)
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
High earnings volatility and inconsistent track record (e.g., -3600% surprise in 2023)
Leverage is elevated with Debt/Equity ratio of 1.23 and no Altman Z-Score to assess bankruptcy risk
AI Fair Value Estimate
Based on comprehensive analysis
$9.33
+245.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
65
60
45
40
0
AI Verdict
Cautiously optimistic with significant execution and sustainability risks
Key drivers: Bullish analyst target, Improving recent earnings surprises, Low forward P/E, High gross margin, Weak Piotroski score and profitability
Confidence
70%
Value
65/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.43 is low, suggesting potential undervaluation
- Forward P/E of 15.88 is well below sector average
- Price/Book of 1.15 indicates near-book valuation
Watchpoints
- No Graham Number or intrinsic value provided
- Lack of EV/EBITDA and PEG due to unprofitability
Future
60/100
Ref Growth rates
Positives
- Q/Q Earnings Growth of +33.30%
- YoY EPS Growth of +40.0%
- Analyst target implies strong future upside
Watchpoints
- Revenue Growth YoY is -16.20%
- Forward earnings still negative
Past
45/100
Ref Historical trends
Positives
- Recent quarters beating estimates (3 of last 4)
- Some history of large positive earnings surprises
Watchpoints
- Extremely volatile earnings (e.g., -3600% surprise)
- Long-term 5Y price return down 98.4%
- History of large negative surprises
Health
40/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 1.23 and Quick Ratio of 1.00 indicate minimal short-term liquidity
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- ROE of -50.23% and negative profit margins
- No Altman Z-Score to assess bankruptcy risk
- Debt/Equity of 1.23 is high for a loss-making firm
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid (Dividend Yield: N/A)
- Dividend Strength: 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.7
Analyst Target
$9.33
Upside/Downside
+245.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AYTU and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AYTU
Aytu BioPharma, Inc.
Primary
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
|
TELA
TELA Bio, Inc.
Peer
|
-95.4% | -93.3% | -29.1% | -57.4% | -18.9% | +12.7% |
|
ICCM
IceCure Medical Ltd
Peer
|
-97.0% | -71.2% | -71.9% | -62.9% | -51.7% | +7.7% |
|
KYNB
Kyntra Bio, Inc.
Peer
|
-98.6% | -98.5% | +10.3% | -32.0% | +0.7% | +2.3% |
|
DARE
Daré Bioscience, Inc.
Peer
|
-91.0% | -85.0% | -38.6% | -21.2% | +15.7% | -2.8% |
AYT
Aytu BioPharma, Inc.
Primary
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
TEL
TELA Bio, Inc.
Peer
5Y
-95.4%
3Y
-93.3%
1Y
-29.1%
6M
-57.4%
1M
-18.9%
1W
+12.7%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%
KYN
Kyntra Bio, Inc.
Peer
5Y
-98.6%
3Y
-98.5%
1Y
+10.3%
6M
-32.0%
1M
+0.7%
1W
+2.3%
DAR
Daré Bioscience, Inc.
Peer
5Y
-91.0%
3Y
-85.0%
1Y
-38.6%
6M
-21.2%
1M
+15.7%
1W
-2.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
15.88
PEG Ratio
N/A
P/B Ratio
1.15
P/S Ratio
0.43
EV/Revenue
0.36
EV/EBITDA
3.86
Market Cap
$27.51M
Profitability
Profit margins and return metrics
Profit Margin
-20.52%
Operating Margin
-10.83%
Gross Margin
67.56%
ROE
-50.23%
ROA
0.61%
Growth
Revenue and earnings growth rates
Revenue Growth
-16.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+33.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.23
Moderate
Current Ratio
1.23
Good
Quick Ratio
1.0
Poor
Cash/Share
$3.2
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-13
$-0.09
+52.1% surprise
2025-09-23
$-0.08
-27.3% surprise
2025-05-14
$0.21
+223.5% surprise
2025-02-12
$0.13
+146.4% surprise
Healthcare Sector Comparison
Comparing AYTU against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-50.23%
This Stock
vs
-88.14%
Sector Avg
-43.0%
(Below Avg)
Profit Margin
-20.52%
This Stock
vs
-16.28%
Sector Avg
+26.1%
(Superior)
Debt to Equity
1.23
This Stock
vs
2.66
Sector Avg
-54.0%
(Less Debt)
Revenue Growth
-16.2%
This Stock
vs
124.04%
Sector Avg
-113.1%
(Slower)
Current Ratio
1.23
This Stock
vs
4.47
Sector Avg
-72.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | |
|
TELA
TELA Bio, Inc.
|
BEARISH | $28.23M | - | -223.4% | -48.4% | $0.63 | Compare |
|
ICCM
IceCure Medical Ltd
|
BEARISH | $26.25M | - | -188.8% | -% | $0.32 | Compare |
|
KYNB
Kyntra Bio, Inc.
|
BEARISH | $29.02M | - | -% | 2848.6% | $7.17 | Compare |
|
DARE
Daré Bioscience, Inc.
|
BEARISH | $25.77M | - | -% | -% | $1.77 | Compare |
AYTU
Aytu BioPharma, Inc.
NEUTRAL
Mkt Cap
$28M
P/E
-
ROE
-50.2%
Price
$2.7
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-03 | LIU VIVIAN H | Director | Stock Award | 10,000 | - |
| 2025-10-03 | DISBROW JOSHUA R. | Chief Executive Officer | Stock Award | 53,946 | - |
| 2025-10-03 | DOCKERY CARL C | Director | Stock Award | 10,000 | - |
| 2025-10-03 | DISBROW JARRETT T | Officer | Stock Award | 32,106 | - |
| 2025-10-03 | SELHORN RYAN J | Chief Financial Officer | Stock Award | 33,743 | - |
| 2025-10-03 | PYSZCZYMUKA GREG | Officer | Stock Award | 12,500 | - |
| 2025-10-03 | JAIN ABHINAV | Director | Stock Award | 10,000 | - |
LIU VIVIAN H
Director
2025-10-03
10,000 shares
DISBROW JOSHUA R.
Chief Executive Officer
2025-10-03
53,946 shares
DOCKERY CARL C
Director
2025-10-03
10,000 shares
DISBROW JARRETT T
Officer
2025-10-03
32,106 shares
SELHORN RYAN J
Chief Financial Officer
2025-10-03
33,743 shares
PYSZCZYMUKA GREG
Officer
2025-10-03
12,500 shares
JAIN ABHINAV
Director
2025-10-03
10,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
Ascendiant Capital
2025-12-10
Buy
Buy
Maxim Group
2025-09-25
Buy
Buy
Ascendiant Capital
2025-09-25
Buy
Buy
Past News Coverage
Recent headlines mentioning AYTU from our newsroom.
Newest → oldest
No matching news yet.